In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2

New antiretroviral drugs are needed to treat HIV-2 infected patients failing therapy. Herein, we evaluate the activity of novel reverse transcriptase inhibitors tenofovir alafenamide (TAF) and OBP-601(2,3-didehydro-3-deoxy-4-ethynylthymidine) against primary isolates from HIV-2 infected patients exp...

ver descrição completa

Detalhes bibliográficos
Autor principal: Bártolo, Inês (author)
Outros Autores: Borrego, Pedro (author), Gomes, Perpétua (author), Gonçalves, Fátima (author), Caixas, Umbelina (author), Pinto, Inês V. (author), Taveira, Nuno (author)
Formato: article
Idioma:eng
Publicado em: 2019
Assuntos:
HIV-2
Susceptibility to TAF
TDF and OBP-601
Resistance mutations
Texto completo:http://hdl.handle.net/10400.26/30647
País:Portugal
Oai:oai:comum.rcaap.pt:10400.26/30647

Texto Completo

http://hdl.handle.net/10400.26/30647

Registros relacionados